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a b  s  t  r a  c t
As people  age  they  become increasingly  susceptible to  chronic  and  extremely  debilitating  brain diseases.
The precise  cause of the  neuronal degeneration  underlying these  disorders, and  indeed  normal  brain
ageing  remains however elusive. Considering the  limits of existing preventive  methods,  there  is a desire
to  develop  effective  and  safe strategies.  Growing  preclinical and  clinical  research  in healthy  individuals
or  at the  early stage of cognitive  decline has  demonstrated  the  beneﬁcial  impact  of nutrition  on cognitive
functions.  The present  review is  the  most recent  in a series  produced  by  the  Nutrition and Mental  Per-
formance  Task  Force under  the  auspice of the  International Life Sciences  Institute  Europe (ILSI  Europe).
The latest  scientiﬁc advances  speciﬁc to how dietary  nutrients  and  non-nutrient may  affect cognitive
ageing  are  presented.  Furthermore,  several key  points  related  to  mechanisms  contributing  to brain  age-
ing,  pathological  conditions affecting  brain function, and brain  biomarkers are  also  discussed.  Overall,
ﬁndings  are  inconsistent and  fragmented and more  research  is warranted  to determine the  underlying
mechanisms  and  to establish  dose-response  relationships for  optimal brain  maintenance  in different
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population  subgroups.  Such approaches are  likely to  provide the  necessary  evidence to develop  research
portfolios  that will  inform about new dietary  recommendations  on how  to prevent  cognitive  decline.
©  2016 The Authors.  Published  by  Elsevier B.V.  This  is an open  access article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The signiﬁcant increase in  average life expectancy is  one of
society’s great achievements which has been associated with a
shift in the leading causes of illnesses from infectious to non-
communicable diseases. It  is  well known that the percentage of
populations categorized as elderly (e.g.  65 years and older) will
increase dramatically in almost every country in  the next few
decades. By 2060, the elderly population will be expected to grow
from 17.4% to nearly 30% worldwide (European Comission and
Eurostat, 2012). At  the same time, there is a  wealth of disparate
data related to how nutrients, non-nutrient, food components
and whole diets may  impact on cognitive health and ageing.
Numerous epidemiological studies indicate that long-term intake
of a Mediterranean diet (emphasizing amongst others fruits, veg-
etables, and olive oil) correlates with better cognition in aged
populations (Feart et al., 2010; Scarmeas et al., 2009; van de Rest
et al., 2015). Mechanistic investigations in vitro and in  animal
models have demonstrated that anti-inﬂammatory compounds in
plants stimulate neurogenesis and protect neurons from noxious
insults. However, such studies could not be replicated in humans
(Stangl and Thuret, 2009) and treatments with ibuprofen, or  foods,
such as turmeric, although decrease pro-inﬂammation biomarkers
only rarely show any pro-cognition effects, at least in  intervention
trials (Lee et al., 2013; Townsend and Pratico, 2005). Due to the lack
of highly sensitive cognitive test  batteries and control for individual
differences, diets and nutrients are not proven to robustly alleviate
cognitive decline over short periods.
In the past 10 years, high-calorie/low-dietary ﬁbre diets and risk
and incidence of diet-related diseases (i.e.  Type 2  Diabetes Melli-
tus (T2DM) or cardiovascular disease (CVD)) have been associated
with age-related cognitive decline (Beydoun et al., 2008; Loef and
Walach, 2013; Nepal et al., 2014; Whitmer et al., 2005). Avail-
able data on beneﬁcial effects of several ingredients or nutrients
(e.g.  dietary ﬁbre, low-glycaemic carbohydrates, resveratrol and
docosahexaenoic acid (DHA)) suggest that  their consumption may
decrease glycaemic spikes or improve plasma cholesterol or triglyc-
erides levels, thus having the potential to help prevent cognitive
decline (Greenwood, 2003; Greenwood and Winocur, 2005).
Randomized placebo-controlled trials (RCTs) are the gold stan-
dard to  conﬁrm the effect of a  nutritional intervention on cognitive
decline, maintenance or improvement. However, such trials may
be impossible to conduct for some nutrients, where subtle effects
are  predicted to add up  over decades and may  be signiﬁcantly inﬂu-
enced by individual differences in  the rate of cognitive decline.
Currently, there are no dietary recommendations or accepted
health claims referring to age-related cognition on the foodstuffs
marketed. It may  be expedient to  weigh evidence from pilot, cohort,
case control and animal studies, and evaluate these together, rather
than taking into account only RCTs. Some nutrients may  exhibit
stronger effects in conjunction with others, and thus, one aim of
this review is to weigh effects of nutrients in  isolation, such as
DHA taken as ﬁsh oil supplements, versus combinations of  partic-
ular bioactives such as found in the Mediterranean diet. Although
the present review is  mostly focused on the role of nutrients in cog-
nitive decline, it also offers some insights about different aspects
related to  the process of ageing. Thus, it highlights important
considerations about normal and pathological ageing and its mea-
surement through the use of biomarkers of cognitive status, as well
as metabolic conditions that are considered as risk factors for cog-
nitive decline. Therefore, the main goal of the present review is  to
provide the most recent evidence from human observational and
intervention trials along with key mechanistic studies in  cell and
animal models, on the current state of knowledge on nutrition and
healthy brain ageing.
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2. Normal and pathological decline in  cognitive function
Major aspects of human cognitive function are inﬂuenced by
a variety of factors including genetics, lifestyle, nutrition, disease,
trauma, medicines, as well as both normal and pathological age-
ing. The group led by  Salthouse (2010) has compiled a  convincing
body of evidence demonstrating that notable age-related decline in
cognitive function occurs in healthy individuals starting from the
late 20s and continuing throughout the adult lifespan. Some head-
line conclusions from this research are that such decline occurs in
all individuals, concerns a  wide range of major aspects of cogni-
tive function (i.e.  not simply memory) and are marked in  nature
(e.g. up to 2 standard deviations). Such ﬁndings have now been
widely replicated (Wesnes and Ward, 2001; Wesnes and Edgar,
2014) and an important message is  that the same aspects of cog-
nition which decline with ageing also decline (at a  much greater
rate) both in Mild Cognitive Impairment (MCI) and in  the dementias
(Wesnes and Lenderking, 2012). Despite this compelling evidence,
there is little regulatory support for the development of medicines
to treat such declines. It is proposed that this time-based deteri-
oration to crucial aspects of mental ability in  healthy individuals
should receive the same aggressive treatments as other age-related
declines (such as eyesight deterioration). Nevertheless, there was
a temporary surge of interest in this area over 25 years ago when
the National Institute of Mental Health (NIMH) workgroup deﬁned
operational criteria for age-associated memory impairment (Crook
et al., 1986). Then, over the next few years a  variety of drugs
were evaluated to treat this condition with some limited success
(e.g. phosphatidylserine) (Crook et al., 1991). Criticism from some
quarters that the pharmaceutical industry was creating a new con-
dition simply to sell drugs to  treat something which occurs in
most individuals (O’Brien, 1999) led the industry to  move away
from this area and concentrate on pathological declines such as
MCI, Alzheimer’s disease (AD) and other dementias (Wesnes and
Ward, 2001). In fact, during the last 10 years the news for novel
drugs to treat MCI and AD has been overwhelmingly negative. No
novel treatment has been approved for treating AD, despite a  mas-
sive worldwide research effort which has been overshadowed by
the  failure of over a hundred putative treatments (Becker et al.,
2008; Cummings et al., 2014; Mullard, 2012). This has led the
ﬁeld to move its focus to  prodromal and even preclinical stages
of dementia, stimulated by  diagnostic criteria designed in 2007 to
capture earlier stages based on early episodic memory loss along-
side with biomarker evidence of disease pathology (Dubois et al.,
2007). These criteria have been further reﬁned (Albert et al., 2011;
Dubois et al., 2010) and the goal posts broadened considerably
with operational research criteria for preclinical AD (Sperling et al.,
2011). Preclinical AD is particularly relevant as the trials would
involve cognitively healthy elderly populations. Regulatory author-
ities have become proactive. In fact, in a recent publication authored
by the Food and Drug Administration (FDA) ofﬁcials, the point was
made that in preclinical AD trials, where functional impairment
would be difﬁcult to assess, it could be feasible to approve a  drug
through the FDA’s accelerated approval pathway on  the basis of
assessment of cognitive function alone (Kozauer and Katz, 2013).
Therefore, a regulatory avenue has been opened in  addition to new
clinical criteria, and large trials in preclinical AD are already under-
way.
3. Biomarkers of cognitive status
AD is a slowly progressive neurodegenerative disorder with
duration of several decades (Jack et al., 2011) showing 3 dif-
ferent phases; one preclinical and asymptomatic, a second one
when cognitive performance starts to decline, and the last phase
characterized by the typical memory-dominant dementia syn-
drome, which impairs everyday activities and patient autonomy
(McKhann et al., 2011). In neuropsychiatric tradition, AD could
only be diagnosed in a clinical setting if dementia was  present, but
a paradigm shift towards a more biologically deﬁned AD diagno-
sis has been observed in recent years. The new National Institute
on Ageing-Alzheimer’s Association (NIA-AA) guidelines conceptu-
alize AD as a  progressive disorder including all possible stages
from pre-symptomatic to  severely demented (Jack et al., 2011;
McKhann, 2011). This way  of thinking implies that tissue changes
precede the onset of clinical signs by many years, and neuropatho-
logical lesions can be found in  elderly individuals who presently
do  not have, and may  not live long enough to ever suffer from
cognitive impairment and associated disability (Giaccone et al.,
2011).
During the past 30 years, a  large body of evidence has
been accumulated indicating that a  cascade of events related
to the faulty production, degradation and clearance of amyloid-
 protein (A)  lie at the heart of AD pathogenesis. Upstream
events within this cascade include the overproduction of the
amyloid- precursor protein (APP)  caused by rare mutations
in the APP, PSEN1 or PSEN2 genes, malfunctioning of A-
degrading proteases and impaired clearance as a  result of
ineffective active or passive transport mechanisms (Jack et al.,
2011). The imbalance between production and clearance results
in  excessive amounts of A, which are believed to trigger a
sequence of subsequent, i.e.  downstream, pathological changes
such as loss of synapses and neurons, impaired glucose utilisation,
oxidative damage, brain metabolic reduction, tau  hyperphos-
phorylation and associated neuroﬁbrillary tangle formation, A
deposition in plaques and eventually neurotransmitter changes and
widespread neurodegeneration. This complex cascade of  patho-
logical events continues throughout the course of AD,  leading to
an accumulation of structural and functional cerebral damages
causing the typical clinical feature of disease (Jack et al., 2011,
2010a,b).
The hope for disease modiﬁcation as well as technological
advances in biomarker discovery fuel the search for biological
indicators of the AD pathophysiological process, which can be
used to  identify neurodegeneration independently of its clinical
manifestations (Hampel et al., 2010). Ideally, such a biomarker,
alone or in  combination with other markers, would distinguish
between individuals with and without AD pathology. Furthermore,
pathophysiological markers may  also offer the added beneﬁt of
directly assessing response to treatment options that target core
processes of AD pathogenesis. However, biomarker evidence of
treatment efﬁcacy should not replace clinical evidence of patient
beneﬁt.
Currently available AD biomarkers can generally be grouped
into two categories. The ﬁrst category comprises markers that indi-
cate the type of pathology present, including cerebrospinal ﬂuid
(CSF) levels of A1-42, total tau (tTau) and phosphorylated tau
(pTau)181 (Blennow et al., 2010) and positron emission tomography
(PET) tracers of ﬁbrillar amyloid such as ﬂutemetamol, ﬂorbetapir,
ﬂorbetaben and Pittsburgh Compound B (Herholz and Ebmeier,
2011). The second category consists of markers that provide infor-
mation on the topography of pathological changes, such as MRI  and
ﬂuorodeoxyglucose PET (Dubois et al., 2010). Published evidence
consistently shows that these biomarkers, alone or in combination
with psychometric test results, offer an added value for the diagno-
sis of the early clinical stages of AD. Novel biomarkers that are more
closely related to the core pathophysiological processes of AD are
currently in  development (Perneczky et al., 2014)  such as soluble
forms of APP, which can be measured in  CSF (Perneczky et al., 2011)
and blood (Perneczky et al., 2013).
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4. Metabolic and molecular mechanisms contributing to
brain ageing
4.1. Cardiometabolic risk factors
The role of cardiometabolic health, including vascular stiffness
and reactivity in cognitive health and decline are being increas-
ingly recognized. In a  1-year longitudinal study in  patients older
than 80 years higher aortic stiffness was associated with more
pronounced decline in cognitive function (Benetos et al., 2012),
and microvascular function was signiﬁcantly impaired in  demen-
tia patients as compared to controls (Khalil et al., 2007). Although,
the  line between normal and pathological ageing may  not be well-
deﬁned, certain metabolic alterations such as obesity or Type 2
diabetes mellitus (T2DM) may  account for an increased risk of
suffering age-related cognitive decline, especially in  the elderly.
The dramatic global increase in  the incidence of obesity over the
last 50 years is having a large effect on the incidence of many
chronic diseases including T2DM and dementia. Indeed, more than
half (52%) of the adult population in  the 27 European Union (EU)
member states are overweight (BMI =  25.0–29.9 kg/m2) or obese
(BMI ≥ 30.0 kg/m2) (Eurostat statistics database et al., 2012)  with
an average EU obesity incidence of 17% in  adults (Eurostat statistics
database et al., 2012). An excess of adipose tissue and its associated
co-morbidities in middle-age, has emerged as a  signiﬁcant risk fac-
tor for age-related cognitive decline. A 27-year US cohort which
consisted of overweight and obese individuals (aged 40–45 years)
showed an odds-ratio (OR) 95% conﬁdence interval (CI) of demen-
tia of 1.35 (1.14–1.60) and 1.74 (1.34–2.26), respectively, relative
to normal weight individuals (Whitmer et al., 2005). Comparable
effect sizes of 1.5–2.0 OR have been documented in more recent
analyses, including a meta-analysis, which reported an attributed
risk of 12% of total dementia and 21% of AD associated with obesity
in a US population (Beydoun et al., 2008). Indeed, including midlife
obesity in forecast models typically results in  a  10–20% higher
prevalence of dementia (Loef and Walach, 2013; Nepal et al., 2014)
than the doubling of prevalence predicted by  2030 based only on
ageing-related demographics (Alzheimer’s Disease International,
2009).
Metabolic syndrome (MetS) and T2DM have comparable
impacts on dementia risk and have been reported in overweight
and obese individuals, respectively. For example, a relative risk
of  1.20 (1.02–1.41; 95% CI) of cognitive impairment was  evident
in MetS subjects as compared to  healthy controls (Yaffe et al.,
2004). Furthermore, in  a  recent meta-analysis including 19 stud-
ies, subjects with diabetes presented higher risk for AD (relative
risk (RR):1.46, 95% conﬁdence interval (CI): 1.20–1.77), vascular
dementia (RR: 2.48, 95% CI:  2.08–2.96), any dementia (RR: 1.51,
95% CI: 1.31–1.74) and MCI  (RR: 1.21, 95% CI: 1.02–1.45) than
those without (Cheng et al., 2012). Interestingly, these results also
showed that diabetes increases the risk for AD independently of
APOE4 status, although subjects with both diabetes and APOE4 had
the highest risk for AD (Cheng et al., 2012).
A growing body of epidemiological evidence is also suggesting
that metabolic syndrome (MetS) and its associated compo-
nents (impaired glucose tolerance, abdominal or central obesity,
hypertension, hypertriglyceridemia, and reduced high-density
lipoprotein cholesterol) may  be important in the development of
age-related cognitive decline, mild cognitive impairment, vascu-
lar dementia, and AD (Frisardi et al., 2010; Panza et al., 2012b).
Although some understanding exists regarding the role of glucose
and insulin within the central nervous system (CNS), the physio-
logical and molecular basis of the contribution of obesity and its
comorbidities to cognitive decline, along with causality and inde-
pendence of associations are poorly understood (Freeman et al.,
2014), but are likely to  include: a) impaired vascular function
and brain perfusion (Benetos et al., 2012; Elias et al., 2009; Khalil
et al., 2007; Picano et al., 2014), b)  low grade inﬂammation, includ-
ing altered adipose tissue production of adipokines (Kiliaan et al.,
2014; Song and Lee, 2013), c) poor glucose tolerance and utilisation
(Lamport et al., 2009),  and d) loss of insulin sensitivity indepen-
dent of the impact on glucose metabolism (Calvo-Ochoa and Arias,
2015; De Felice, 2013; Park et al., 2000; Williamson et al., 2012).
In this context, AD is currently proposed as an “insulin resistant
brain state” (Craft et al., 2013).  In addition, insulin in  the CNS
is largely derived from the periphery (pancreas) with some local
insulin produced by the dentate gyrus (hippocampus) and olfactory
system (Kuwabara et al., 2011). In neurons, insulin regulates energy
metabolism, differentiation, growth, survival, synaptic plastic-
ity and neurotransmission and promotes hippocampal long-term
potentiation (LTP), learning and memory (Bingham et al., 2002;
Calvo-Ochoa and Arias, 2015; Kuwabara et al., 2011; Skeberdis
et al., 2001). Therefore, a loss of insulin sensitivity would be pre-
dicted to  negatively impact on these metabolic processes.
Neuroinﬂammation has been associated with the risk of devel-
oping dementia and cognitive decline (McGeer and McGeer, 1999;
Yaffe et al., 2003). In a  longitudinal study, Yaffe and colleagues
examined the association between MetS and cognitive change in
elderly Latinos. Participants with MetS with high inﬂammation
(median serum CRP level  ≥3.2 mg/L) had signiﬁcantly reduces cog-
nitive function, measured by using the Modiﬁed Mini-Mental State
Examination (3MS) than those without high inﬂammation. In this
study, the individual components of MetS were also examined
as predictors of cognitive change. The authors concluded that, in
elderly Latinos, the composite measure of metabolic syndrome is
a  greater risk for cognitive decline than its individual components,
with the possible exception of impaired glucose control and high
blood pressure (Yaffe et al., 2007).
Interestingly, Solfrizzi and colleagues concluded in  a  longitudi-
nal Italian population-based sample, that MetS appeared to be a
risk factor of progression to  dementia in  MCI patients. However,
it is  unknown how MetS could increase the risk of dementia in
these patients (Solfrizzi et al., 2011). Unfortunately, in this study,
the number of events of progression to dementia in MCI  patients
was not  sufﬁcient to allow the authors to analyse the effect of MetS
on the risk of developing a subtype of dementia.
4.2. Anaemia
The role of anaemia on cognition is  still controversial and the
potential mechanisms by which anaemia could impact on cogni-
tive  decline are still not understood (Andro et al., 2013).  The main
hypothesis proposed, points to  the role of the chronic low oxy-
genation of the aerobic cortical tissue, even more in  the presence
of compromised compensatory processes due to the neurode-
generative or vascular pathology underlying MCI  (Andro et al.,
2013). Alternatively, anaemia has been suggested as a  frequent
complication of chronic kidney disease which leads to decreased
erythropoietin levels that in turn may  increase the risk of neurode-
generation (Andro et al., 2013).
The number of studies investigating the relationship between
anaemia or haemoglobin concentration and dementia or cogni-
tive  decline has increased in recent years. However, the results
of these studies are inconsistent (Lucca et al., 2008). Conﬂicting
results have been found in  studies investigating the association
between anaemia or haemoglobin concentration and dementia or
AD or vascular dementia mainly due to not  appropriately adjusted
confounding factors or inaccurate methodology (Lucca et al., 2008).
Consequently, larger size, prospective, more representative and
methodologically robust studies are  needed to establish the pos-
sible effect of mild anaemia on cognition in  elderly persons.
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4.3. Oxidative stress
The brain is  a  highly metabolically active tissue that relies on
oxidative phosphorylation as a  way for maintaining energy. The
level of oxidative stress plays a  pivotal role in brain functioning
and growing evidence suggests a  delicate balance between free
radicals production and brain protection or damage (Chakrabarti
et al., 2011). A moderate oxy-radical production by the mitochon-
dria, reported as physiological level of oxidative stress, is  known
to up regulate the mitochondrial biogenesis program and brain
antioxidant capacity, and to act in brain protection. By contrast,
accumulation of oxidative damages is a  key mechanism of the age-
ing process and a  common feature of ageing brain. That, together
with age-related mitochondria decay, causes alterations of cellular
architecture within the brain, and raises the fact that uncontrolled
free radical production is  a  major contributor to  the loss of neuronal
homeostasis and neurodegenerative diseases development (Wang
et al., 2014).
4.4. Neuroinﬂammation
It has been observed in  animal models of AD and Parkin-
son Disease, that systemic inﬂammation generates an exacerbated
immune response in  the CNS through the local innate immune sys-
tem. Then, the priming pattern triggered by  activated microglia,
can be inﬂuenced not only by the sequence of neurodegeneration
but also by the systemic inﬂammation or other secondary stimuli.
Priming makes the microglia susceptible to a  secondary inﬂamma-
tory stimulus, which can then trigger an exaggerated inﬂammatory
response (Perry and Holmes, 2014). Activated microglia has the
capacity to synthesize a  wide range of pro-inﬂammatory and
anti-inﬂammatory cytokines and molecular mediators, which con-
tribute to the systemic inﬂammatory milieu and to the progression
of neurodegenerative disease (Perry, 2004; Perry et al., 2007). Dur-
ing neurodegenerative events, neural damage leads to  a  loss or
down regulation of neural ligands that bind to inhibitory recep-
tors on the microglia, resulting in a  reduced microglia inhibition.
Priming of macrophages has been widely studied in vitro follow-
ing the exposure to  IFN-γ and lipopolysaccharide (Schroder et al.,
2006). Low doses of lipopolysaccharides are  sufﬁcient to  trigger
microglia activation and sickness behaviour in  both humans and
non-human primates (Brydon et al., 2008; Hannestad et al., 2012;
Harrison et al., 2009).
Nevertheless, other molecules expressed in  the injured brain
such as the colony-stimulating factor-1 (CSF-1) (Chapoval et al.,
1998) and C C motif chemokine 2 (CCL2) (Bhattacharyya et al.,
2002; Rankine et al., 2006) can also prime microglia. Activation of
CSF-1 receptor (CSF-1R) by  CSF-1 and IL-34 (Greter et al., 2012;
Wang et al., 2012) drive microglia proliferation (Gomez-Nicola
et al., 2013), which is signiﬁcantly important since the primed
state and the increased number of microglia both contribute to  the
exaggerated response observed in the brain in neurodegenerative
disorders.
In addition, mutations in  CSF-1R also lead to  important white
matter damages associated with progressive dementia but the
disease onset and severity strongly depend on the mutation
(Nicholson et al., 2013). The effects of the mutation on white mat-
ter region along with the fact that microglia remains more in white
matter than in  grey matter, suggest that microglia may  have an
important role in myelin or axonal homeostasis.
Ageing, as the main risk factor for AD development, occurs
with a chronic, low-grade systemic upregulation of the proin-
ﬂammatory T helper type 1 response and a  relative decline in
the anti-inﬂammatory T helper type 2 response (Franceschi et al.,
2007). A study which examined brain samples from patients with
mild or late-stage AD investigated the type of the inﬂammatory
response (M1- or M2-like: CNS activated microglia corresponding
to ‘cytotoxic’ and ‘repair’ subpopulations of macrophages in  other
organs) and tried to ﬁnd serum markers that were associated with
these two phenotypes (Sudduth et al., 2013). Noticeably, the M1-
like state was associated with increased levels of CCL3 and the
M2-like state with increased serum levels of IL-1 receptor antago-
nists.
It is well known that in the ageing population, an increas-
ing number of individuals have more than one systemic disease
(Barnett et al., 2012), which indicates that systemic inﬂammation
has a relevant importance as a  risk factor for AD. The group of Perry
et al. has demonstrated that systemic inﬂammation and acute infec-
tions are associated with an enhanced rate of cognitive decline
(Holmes et al., 2009) and increased symptoms of sickness in AD
patients (Holmes et al., 2011).
Therefore, according to  all these data, the monitoring and
prompt treatment of systemic disease, inﬂammation and infection
may delay neurodegenerative disease progression and improve
quality of life  (Perry and Holmes, 2014).
4.5. AMPK signalling and autophagy
Although, the precise neurobiological origin of dementia
remains controversial, systems medicine approaches integrating
recent advances in molecular technologies with computational
methods are able to address this complexity and to identify key
molecular hubs relevant for neurodegenerative dementia. These
approaches, supported by the fast growing knowledge of human
interactome, offer a platform to systematically explore not only
the molecular complexity of a  particular disease but also the
molecular relationships among apparently distinct diseases. The
group of Caberlotto et al. (Caberlotto et al., 2013) applied these
novel systems biology approaches not  only to clarify the molecu-
lar basis of AD, but  also to  characterize the molecular alterations
of the subgroup of neurodegenerative disorders with the shared
core symptom of dementia. By convergent analysis of multi-
dimensional datasets, their study on AD revealed a  major role of
metabolism and, predominantly, of AMP-activated kinase (AMPK)
as a  central dis-regulated process in  AD. AMPK is a  core sig-
nalling pathway in cellular homeostasis and crucial regulator of
energy metabolism. Through the examination of neurodegenera-
tive dementias, they integrated not only the current knowledge on
the speciﬁc diseases, but also the molecular targets of drugs for the
treatment of dementia. This study underlined once more the role
of AMPK signalling and autophagy, a  self-degradative process that
is important for balancing sources of energy in  response to  nutri-
ent stress, as the molecular basis of neurodegenerative dementia
(Caberlotto and Nguyen, 2014). Similar results were obtained from
the integrative analysis of AD and T2DM, two multifactorial dis-
eases of ageing with marked common pathophysiological features,
which conﬁrmed the autophagy pathway as the molecular mecha-
nism altered in  both diseases (Caberlotto and Nguyen, 2015).
5.  Prevention of cognitive decline through nutritional and
other lifestyle interventions
Preclinical and clinical studies provide valuable data regarding
the effect of particular dietary patterns and/or speciﬁc nutrients
on cognitive function. For example, deleterious dietary habits
(overfeeding, high caloric/low dietary ﬁbre diet or consumption
of low antioxidant nutrients) and sedentary lifestyle, or emo-
tional stress, have been reported as key environmental factors for
oxidative stress and brain disorders (Martin et al., 2006; Mattson,
2012). Insulin resistance (IR) which is  found in overweight, MetS,
and T2DM individuals is  one of the leading causes of  oxidative
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stress. Given the negative effects of IR, inﬂammation and oxidative
stress in brain, several dietary components, acting as antioxi-
dant, anti-inﬂammatory and/or insulin action potentiating factors,
could positively participate in a  preventive nutritional strategy
for healthy ageing of brain. It is  therefore necessary to increase
research on the beneﬁts of nutrition and healthy eating habits
in order to identify the best dietary recommendations in  human
population. These will enable the prevention or delay of diseases
and disability and increase quality of life in the elderly (Roman-
Vin˜as and Serra-Majem, 2014). Among existing dietary patterns,
adherence to a Mediterranean diet is  associated with less cognitive
decline, dementia, or AD (Cao et al., 2015; van de Rest et al., 2015)
and ﬁts the notion of a healthy dietary pattern (Maillot et al., 2011).
For example, a meta-analysis showed that  greater adherence to a
Mediterranean-style dietary pattern during older adulthood was
associated with a lower risk of developing several different health
outcomes such as CVD, neurodegenerative disorders, cancer and
overall mortality (Soﬁ et al., 2010). In  general, the Mediterranean
diet is characterized by a high intake of vegetables, fruits, cereals,
nuts and olive oil (as the principal source of added fat), a mod-
erate intake of ﬁsh and alcohol (mostly wine), and a  low intake
of  dairy products, red meat and meat products (Bach-Faig et al.,
2011). Higher adherence to  a  Mediterranean-style diet was  asso-
ciated with higher intakes of several antioxidant nutrients, and
other food bioactives such as polyphenols, which are present in
fruits, vegetables, cereals and beverages such as wine, coffee and
tea. Particularly, the role of coffee and caffeine consumption in
later-life cognitive decline and dementia has been examined in  a
recent systematic reviewed by Panza and colleagues including 28
studies, which reported a  potential correlation of moderate con-
sumption of coffee or caffeine-rich beverages with a reduction in
cognitive decline (Panza et al., 2015). Consistent with this, Santos
and colleagues in their systematic review and meta-analysis of caf-
feine and cognitive impairment/decline conducted in nine cohort
and two case control studies reported a  nonsigniﬁcant relative risk
(RR) of 0.98 [95% Conﬁdence Interval (CI): 0.87–1.11], with mod-
erate heterogeneity (Santos et al., 2010). Although, there was  a
lack of a linear dose-response relationship and an association was
not found in all cognitive domains investigated, most of reviewed
population-based studies pointed to  a  neuroprotective effect of
coffee or caffeine consumption against cognitive impairment and
neurodegenerative disorders, with a stronger effect among women
than men  (Arab et al., 2013; Liu et al., 2016; Panza et al., 2015;
Santos et al., 2010).
On the other hand, contrasting ﬁndings also exist between
alcohol consumption and reduced risk of age-related cognitive
decline (Panza et al., 2012a). One recent meta-analysis from epi-
demiological longitudinal studies on older adults suggested that,
light-to-moderate alcohol (usually wine) consumption was asso-
ciated with a 38% reduced risk of incident overall dementia
(Peters et al., 2008). In addition, another meta-analysis reviewed 15
prospective studies including older adults and revealed that light-
to-moderate alcohol intake was correlated with a  25–28% reduction
in risk of AD, vascular dementia, and overall dementia as compared
to alcohol abstinence (Anstey et al., 2009). Finally, a  more recent
systematic review and meta-analysis, which reviewed 74 studies
in older individuals, found that moderate intake of alcohol reduced
cognitive impairment or dementia risk, whereas heavy drinking
was  associated with a  trend toward a higher risk  for cognitive
impairment and dementia (Neafsey and Collins, 2011). Altogether
these studies indicate that light to  moderate alcohol consumption
may protect against AD and dementia. However, the importance of
drinking patterns and speciﬁc beverages remain unknown (Ilomaki
et al., 2015).
5.1. Speciﬁc nutrient levels and age-related cognitive decline
Examination of biochemical indicators of diet in  subject popu-
lations at high risk  for dementia can serve to develop an evidence
base for distinct nutritional requirements for the prevention of
cognitive decline. In addition, comprehensive assessment of nutri-
tional status beyond single or few nutrients can provide insight into
the interactive features between nutrients that may  be relevant to
translational efforts. Thus, these “nutrient biomarker patterns” can
be related to risk for pathological, structural and metabolic changes
that precede cognitive decline and provide insight into mechanism.
One of the earliest structural changes in  the brain that precedes
cognitive decline is  the accumulation of paraventricular and sub-
cortical deep white matter hyperintensities (WMH). These WMH
may  indicate a  breakdown of the blood-brain barrier via ischemic
changes and demyelination of axons (Prins and Scheltens, 2015)
and are a risk factor for cognitive decline. The CSF/plasma ratio of
blood derived albumin is another indicator of BBB function. Here
an increase in the CSF/plasma albumin ratio indicates BBB break-
down (Chen, 2011). The BBB impairment is prevalent in  about
25% of autopsy conﬁrmed AD cases and is associated with more
rapid decline over time. Speciﬁc nutrient concentrations in  the
CSF appear to be inﬂuenced by BBB integrity and this loss of
CNS concentration is  associated with worse prognosis in AD cases
(Bowman, 2012). Another study has demonstrated that BBB func-
tion is  modiﬁable through vitamin therapies (Lehmann et al., 2003).
Thus maintaining BBB health may  be one target for nutritional
therapies aimed at maintaining cognitive function. This area and
underlying changes at the BBB that inﬂuence transport and concen-
tration of nutrients in the brain remain an open area for research.
One report applied a data-driven approach to derive nutrient
biomarker patterns (NBPs) in  the Oregon Brain Ageing Study. The
study included 104 subjects with a mean age of 87 years-old and
free of dementia at baseline. Eight distinct NBPs were identiﬁed and
examined in relation to domain speciﬁc cognitive function and MRI
measures of brain ageing (Bowman et al., 2012). The results were
remarkable in the sense that it appeared that some NBPs were asso-
ciated with global cognition and others mapped more to certain
cognitive faculties only. This would suggest that certain nutrient
combinations operate on general mechanisms in the brain while
others are more discrete. For example, two  NBPs were associated
with more favourable cognitive and MRI  measures: one vitamin
proﬁle (high plasma B vitamins, antioxidants C, and E and vita-
mins D) and another high in plasma -3 fatty acids. The vitamin
proﬁle explained a signiﬁcant portion of variance in  global cogni-
tive  function and particularly, attention, visuospatial and executive
functions. It  was  also associated with less total brain atrophy, a  phe-
nomenon that can be driven by Alzheimer’s type pathology. The
omega -3 pattern appeared more important to vascular aspects
(WMH  volume and executive functions known to be sensitive to
WMH  accumulation). A third pattern characterized by  high trans-
fat was  associated with less favourable cognitive functions across
several domains and more total brain atrophy. Memory function
was best in  those with higher plasma lutein and HDL cholesterol
(Bowman et al., 2012). The NBPs altogether explained 17% of the
total variation in  global cognitive function and 37% of total variation
in total brain volume. These data suggest that biochemical indica-
tors of diet capture magnitudes of effect well beyond what we  are
accustomed to observing in nutrition research. One explanation is
that the nutrient biomarker pattern analysis appreciates “synergis-
tic” features, and another is  that misclassiﬁcation bias of nutritional
exposure is  reduced in comparison to more conventional methods
subject measures of diet in  older adults. In  a  longitudinal study of
older adults at risk for dementia and followed over 4 years, plasma
levels of the two long chain polyunsaturated fatty acids EPA and
DHA were associated with less executive function decline and that
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relationship appeared to be  mediated by WMH  burden (Bowman
et al., 2013). These studies suggest that nutrient biomarker pattern
analysis is a fruitful strategy for studying nutrition, metabolism and
dementia. What and how nutrients inﬂuence the neurobiology that
contributes to age-related cognitive decline warrants much more
research. Combining human induced pluripotent stem cells (iPS)
cells biology, molecular and nutritional neuro-epidemiology and
clinical trials is a  way forward.
5.2. Nutritional assessment for disease prevention
The purpose of nutritional assessment is to  well-characterize
the dietary patterns of individuals, and to assess their exposure
to nutrients and the hundreds of non-nutrients provided by the
diet, for example phytochemicals, food additives, and food con-
taminants. Then, this information can provide scientiﬁc evidence
for the role of dietary factors on human health and well-being.
Other purposes of nutritional assessment are to identify popula-
tion groups who do not have an adequate nutrition for disease
prevention and to develop nutrition programs for at risk popu-
lations in order to monitor their impact. Nutritional assessment
is still a huge challenge, due to the extraordinary heterogeneity
and variability of food choices, and our  limited knowledge of the
composition of foods beyond the ∼60 essential nutrients. Ideal
methods of nutritional assessment should be accurate, sensitive
and applicable to many populations. Currently, available methods
fall into four categories: 1) anthropometric methods, 2) clinical
examination, 3) questionnaires, and 4) biomarkers. Anthropomet-
ric methods such as body mass index (BMI) measurement have
been considered as indicators of the adequacy of energy intake,
but the correlation with diet quality is  very questionable. Clinical
examination has been used to diagnose severe vitamin or  mineral
deﬁciencies. However, this method is  not appropriate for mild deﬁ-
ciencies. Today, dietary assessment is  often conducted using Food
Frequency Questionnaires (FFQs), where subjects must remember
their intake of 10–300 food items over the previous year. Multiple
24 h recalls and food records are more precise but more expensive
and therefore, other new technologies have been developed. Now,
web-based questionnaires are applied in  large cohort studies, as
in the French NutriNet-Santé cohort which includes over 200,000
subjects (Hercberg et al., 2010). Smart phone applications also seem
promising. Nevertheless, even with more technology, question-
naires have inherent limitations due to self-reporting (Maillot et al.,
2011; Roman-Vin˜as and Serra-Majem, 2014; Soﬁ et al., 2010) and
are susceptible to recall bias. Even if statistical techniques have
been developed to  correct measurement errors, questionnaires,
especially FFQs, are suspected to markedly attenuate associations
existing between dietary factors and health outcomes (Bach-Faig
et al., 2011). The last approach for nutritional assessment is the
use of biomarkers, which are quantiﬁed through targeted analy-
ses of bioﬂuids or tissues (Arts and Hollman, 2005; Scalbert et al.,
2005). Biomarkers are independent of all the errors associated
with questionnaires. Today, only a  limited number of validated
biomarkers of food intake have been use in  epidemiology (Arts and
Hollman, 2005; Scalbert et al., 2005),  for example plasma vitamin
C or carotenoids for fruit and vegetable intake, alkylresorcinols for
whole grains, and urine methyl-histidine for meat. Some polyphe-
nols have also been occasionally used as biomarkers of intake for
their main dietary source (van Dam et al., 2013), for example resver-
atrol for red wine or hesperetin for orange (Cassidy et al., 2013).
These biomarkers have been discovered using a hypothesis-driven
approach which means that a speciﬁc compound of the food  was
previously known, its bioavailability was documented and then a
reliable method of analysis could be developed. However, validated
markers discovered with this approach do  not  cover the large diver-
sity of food in the human diet, and many new biomarkers are still
needed.
In  the last decade, metabolomics has emerged as a data-
driven approach for biomarker discovery. The concept of  the food
metabolome has been deﬁned (Scalbert et al., 2014) which repre-
sents all the metabolites present in human tissues and bioﬂuids
that directly derive from the digestion and metabolism of food
chemicals. The food metabolome is affected by both, the dietary
habits and the metabolic capacity of individuals.As an example, a
medium-term controlled intervention study was conducted to ﬁnd
biomarkers of citrus fruits intake (Pujos-Guillot et al., 2013)  where
12 volunteers consumed 500 mL/day of orange juice or control
drink for one month, in  a  cross-over design. The urine metabolomes
analysed by non-targeted high resolution mass spectrometry were
compared at the end of the experimental period. Some expected
candidates biomarkers of orange juice intake were identiﬁed such
as the glucuronides of the citrus ﬂavanones, hesperetin and narin-
genin but new candidates were also found, including some terpene
metabolites as well as proline betaine, which seemed even more
sensitive than the ﬂavanone metabolites (Pujos-Guillot et al., 2013).
Proline betaine has been validated in independent studies, quanti-
ﬁed in a range of foods and was  found almost exclusively in citrus
fruits (Scalbert et al., 2014). This case-study example and many oth-
ers now demonstrate that metabolomics is  an efﬁcient approach to
discover new reliable biomarkers of food intake in  a  data-driven
approach. In total, more than 145 candidate biomarkers have been
proposed for about 20 foods through these food metabolome stud-
ies, and interestingly about 75% were phytochemical metabolites
(Scalbert et al., 2014). These candidate metabolites must be vali-
dated as it has been done for proline betaine.
Since interventional studies for all the foods of the human diet
are not  feasible, the use of cohort samples to identify candidate
intake biomarkers for a  range of foods at the same time  can be
performed. The Phenotyping using Metabolomics for Nutritional
Epidemiology (PhenoMeNEp) project (Rothwell et al., 2014)  used
the SU·VI.MAX2 cohort which is a  well-characterized cohort of
French adults and identiﬁed the strongest discriminant of coffee
intake as Atractyligenine glucuronide, a  phase II  metabolite of a
diterpene, which contributes to the bitter taste of roasted cof-
fee and which has never been reported in signiﬁcant amounts in
any other food sources (Rothwell et al., 2014). Two others strong
discriminants were alkaloids, the diketopiperazine cyclo (isoleucyl-
prolyl) and trigonelline. The three biomarkers were classiﬁed
as excellent biomarkers when their performance was assessed
using receiver-operating characteristic (ROC) curves test. Certainly,
metabolomics-derived coffee biomarkers will be used in the com-
ing years, in  particular to  study the impact of coffee on cognition.
Therefore, proﬁling of urine or plasma metabolomes in inter-
ventions or cohorts studies is efﬁcient to discover new candidate
biomarkers of food intake with a  data-driven approach. A  large
initiative, the FoodBAll project (http://foodmetabolome.org/) has
recently been funded by the European Joint Programming Initia-
tive Healthy Diet for Healthy Life, to identify a large range of new
nutritional biomarkers using metabolomics and to develop a  har-
monized scheme for their validation. Beyond biomarker discovery,
food metabolome proﬁling covering a wide range of bioactives and
biomarkers of intake in bioﬂuids may  become a  new method for
nutritional assessment, once the current technical difﬁculties for
rapid and complete proﬁle annotation will be overcome.
5.3. Micronutrients
As reported by numerous studies in animals and humans, essen-
tial antioxidant trace elements such as Zinc (Zn), Selenium (Se)
and/or insulin sensitizers (Chromium (Cr), Zn) are deeply impli-
cated in brain protection. Selenoproteins, i.e.  Selenoprotein P and
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Glutathione peroxidase, protect brain cells against oxidative stress.
A low Se status increases the risk of cognitive decline. The greater is
the decrease in plasma Se, the higher is the probability of cognitive
decline as indicated in the study of Akbaraly et al. (Akbaraly et al.,
2007). A potential preventive relevance for an optimal Se status
can be therefore speculated to maintain a healthy brain [63]. How-
ever, there is an absence of consistent clinical evidence regarding
whether Se supplementation is  beneﬁcial for the treatment of AD
(Loef et al., 2011).
Zn  also acts positively on brain health by  improving insulin sen-
sitivity and reducing inﬂammation and oxidative stress. However,
so far no beneﬁts on ageing brain are reported after Zn supple-
mentation in humans and even a  potential neurotoxic effect of Zn
accumulation has been observed in AD patients (Nuttall and Oteiza,
2014).
Cr deﬁciency has resulted in insulin resistance and increased
oxidative stress (Roussel et al., 2007). Indeed, in insulin resistant
states (T2DM and MetS), increased Cr intakes are associated with
improved cognitive functions (Krikorian et al., 2010).
5.4. Polyphenols and polyphenol-rich diets
A number of studies have observed protective associations
between dietary polyphenols and the prevention of age-related
chronic diseases such as CVD, diabetes, cancers, osteoporosis and
neurodegenerative diseases (Arts and Hollman, 2005; Scalbert
et al., 2005; van Dam et al., 2013). The strongest evidence of health-
protective properties is for CVDs (Cassidy et al., 2013; Hooper
et al., 2008; McCullough et al., 2012). However, the well-known
biases and measurement errors of dietary assessment tools make
the  precision and accuracy of dietary intake estimations difﬁcult,
and therefore, the associations observed between polyphenols and
health are compromised. As a result, it is still challenging to develop
personalized diet-related recommendations for dietary polyphenol
intake, and further research on  the identiﬁcation and validation of
new nutritional biomarkers is warranted (Zamora-Ros et al., 2012).
In the epidemiologic InCHIANTI study (Invecchiare in Chi-
anti, ageing in the Chianti area), the group of Andres-Lacueva
investigated the associations between total urinary polyphenols,
as biomarkers of total dietary polyphenols (Zamora-Ros et al.,
2011), and all-cause mortality over a 12-year period among older
adult participants (Zamora-Ros et al., 2013). Recently, they also
investigated the associations between total polyphenols and cog-
nitive decline over a 3-year follow-up in older participants free of
dementia at baseline (Rabassa et al., 2015). In these studies, they
observed that participants who consumed a  diet rich in  polyphe-
nols (>600 mg/d) reduced the risk of all-cause mortality and the
risk of cognitive decline in  global cognitive function (using the mini-
mental state examination), and in  attention (using the Trail Making
Test A), by 30%, 47% and 48%, respectively. By contrast, they did not
reduce the risk of decline on executive function measured with the
Trail Making Test B, as compared to those who  consumed diets low
in polyphenols (<500 mg/d). However, no association was  observed
between total urinary resveratrol metabolites, a biomarker of red
wine consumption, and all-cause mortality (Rabassa et al., 2015).
In addition, research on ageing effects has revealed several sig-
nalling pathways which have been experimentally demonstrated
to be involved in the regulation of the ageing process (Salminen and
Kaarniranta, 2012). The central effects of these polyphenols, at the
transcriptomic level conﬁrmed the involvement of speciﬁc molec-
ular component of the AMPK-autophagy systems also in neuronal
and glial cells (unpublished data). The modulation of AMPK and
autophagy could potentially prevent not only neurodegeneration,
but also, in more general terms, it could promote healthy cognitive
ageing.
Cinnamon polyphenols also deserve a  special attention since
they have been reported to reverse in vitro Tau protein aggregation
and break up Tau ﬁlaments (Peterson et al., 2009).  Interestingly,
cinnamon added to the diet also counteracts the increase of amyloid
precursor protein (APP) and Tau protein induced by a  high fat/high
fructose diet in  the rat brain (Anderson et al., 2013).
Polyphenols intake is associated with consumption of fruits
such as grapes, apples, pears, cherries and various berries contain
between 200 and 300 mg of polyphenols per 100 g of fresh weight
(Llorach et al., 2012). Moreover, a  cup of tea or  a  large cup of  cof-
fee contains around 100 mg  of polyphenols. Red wine, chocolate,
legumes and nuts also contribute to the polyphenol intake. Recent
development in analytical techniques and in  metabolomics should
allow the measurement of large sets of polyphenol metabolites as
biomarkers of usual dietary polyphenol intake (Llorach et al., 2012).
This will be essential if we are able, ﬁnally, to make dietary rec-
ommendations regarding polyphenols for improving the autonomy
and quality of life in older people.
5.5. Flavonoids
Amongst polyphenols, the ﬂavonoid subclass has been exten-
sively studied. Given the wealth of available data for these
phytochemicals, we decided to present those as a separate para-
graph. Flavonoids, found in  a variety of fruits, vegetables and
beverages, have been recognized as promising agents capable
of inﬂuencing different aspects of synaptic plasticity resulting
in improvements in  memory and learning in both animals and
humans (Del Rio et al., 2013; Spencer, 2008; Williams and Spencer,
2012).
Accumulating evidence suggests that certain dietary ﬂavonoids
might delay the onset and/or slow the progression of AD (Williams
and Spencer, 2012), but the precise identity of the bioactive form(s)
involved is unknown and critical information about bioavailability
and metabolism has hindered progress in  the ﬁeld. Despite signif-
icant advances in our understanding of the biology of ﬂavonoids
over the past 15 years, they are still mistakenly regarded by many
as acting simply as antioxidants. Yet, ﬂavonoids are  much more
likely to combat neuronal dysfunction and toxicity by  recruiting
anti-apoptotic pro-survival signalling pathways, increasing antiox-
idant gene expression, and reducing A pathology (Williams et
al., 2004; Williamson et al., 2012). There is, however, a  lack of
consensus as to the precise identities of the ﬂavonoids capable of
exerting these effects, partly because ﬂavonoids have notoriously
poor bioavailability and are extensively metabolised in vivo, but
also because most in vitro studies use concentrations that are at
least 100 fold higher than those found following dietary admin-
istration. The group of Williams has started to address some of
these limitations by adopting unbiased in vitro screening strategies
using ﬂavonoids at concentrations that are potentially achiev-
able in  humans to mimic  more closely what occurs in vivo as a
ﬁrst step towards identifying possible dietary interventions for
AD (Cox et al., 2015). Using an APP-GAL4 gene reporter assay in
primary rodent neurones to  screen modulators of APP processing
they identiﬁed a  number of ﬂavonoids that potently inhibit -
secretase activity. Most notably, the ﬂavanols (−)-epicatechin (EC)
and epigallocatechin reduced -secretase activity and A produc-
tion at nanomolar concentrations and reductions in A pathology
were also observed following oral administration of EC to  APP-PS1
mutant mice.
Since EC is readily absorbed and circulates primarily as glu-
curonidated, sulfated, and O-methylated forms in human plasma,
the observed bioactivity is most likely to reside in an EC metabo-
lite. Therefore, Williams’ hypothesis was  that  dietary EC, acting
as a prodrug,  or alternatively a  synthetic EC analogue based on a
metabolite, had the potential to  be developed into a prophylactic
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dietary supplement for AD. The molecular mechanism underlying
this reduction in A production both in wild-type neurons and in
a transgenic model of AD is  not clear but Williams et al. presented
evidence suggesting that EC inhibits the -site amyloid precursor
protein cleaving enzyme 1 (BACE1) (Cox et al., 2015).
A large body of evidence has also emerged from human
intervention studies demonstrating that the consumption of
ﬂavonoid-rich foods is associated with cognitive beneﬁts (for a
review see (Macready et al., 2010; Williams and Spencer, 2012)).
The mechanisms by  which ﬂavonoids exert these actions on cog-
nitive performance are being elaborated, with evidence suggesting
that they may  modulate the activation status of neuronal recep-
tors, signalling proteins and gene expression (Rendeiro et al., 2012,
2013; Williams et al., 2008). Although whether these effects are
mediated directly (i.e.  within the brain) or  from the periphery is
currently unknown.
There is considerable evidence suggesting that neuronal activ-
ity during cognitive performance is tightly coupled to increases
in regional blood ﬂow, a  process known as cerebrovascular cou-
pling (Attwell et al., 2010). Such processes are primarily mediated
by nitric oxide (NO) generated by the activation of both endothe-
lial  nitric oxide synthase (eNOS in  endothelium) and neuronal
nitric oxide synthase (nNOS in  neurons) (Toda et al., 2009). In
particular, NO derived from eNOS activation contributes to cere-
bral arterial dilatation, by migrating to vascular smooth cells and
increasing blood ﬂow at the blood-brain interface (Atochin and
Huang, 2011). Furthermore, there is increasing evidence suggesting
that the cerebrovascular response is  also mediated by  NO liberated
from nNOS-containing neurons adjacent to intra-cerebral arteri-
oles and capillaries (Schroeter et al., 2006).
There is substantial evidence which supports the beneﬁcial
effects of ﬂavonoids, in  particular ﬂavanols (Schroeter et al.,
2006, 2010) and anthocyanins (Rodriguez-Mateos et al., 2013) on
peripheral vascular function and blood ﬂow (measured using ﬂow
mediated dilatation). These effects are mediated by the actions
of absorbed ﬂavonoid metabolites on NO bioavailability, via their
potential to activate eNOS (Schroeter et al., 2006) and/or inhibit
NADPH oxidase activity (Rodriguez-Mateos et al., 2013). Such
improvements in vascular function occur acutely e.g.  ﬂavanols
(cocoa, tea; 1–3 h)  (Schroeter et al., 2006) and anthocyanins (blue-
berry; 1–2 h and 5h+) (Rodriguez-Mateos et al., 2013), are in the
same timeframe and show cognitive improvements using similar
interventions type. Furthermore, ﬂavonoid-induced improvements
in spatial memory in  animal models (Rendeiro et al., 2012; Williams
et  al., 2008)  share similarities with those of exercise-induced alter-
ations in synaptic plasticity in the brain (Bechara and Kelly, 2013;
Cotman et al., 2007), as both involve the activation of Akt/PKB and
the increased expression of BDNF (Spencer, 2009). Indeed, Akt/PKB
activates both eNOS and nNOS, via increases in  intracellular Ca2+
levels in endothelial and neuronal cells, respectively (Dimmeler
et al., 1999; Rameau et al., 2007)  and thus, that may  represent a
common path by which ﬂavonoids and exercise facilitate cognitive
improvements. The central role that  NO plays in  ﬂavonoid-induced
improvements in  human cognition and cerebral blood ﬂow has
been explored by the use of NOS inhibitors, which block the conver-
sion of l-arginine to  l-citrulline and inhibit NO production (Iadecola
et  al., 1994). Future studies should utilize l-arginine analogues
such as nitro-l-arginine methyl ester, nitro-l-arginine, and L-N
G-mono-methyl-arginine (L-NMMA) to help provide information
on the role of NO  and blood ﬂow in mediating cognitive activ-
ity  of polyphenols. Use of L-NMMA  in humans has been shown to
result in a fall in  cerebral blood ﬂow (Shabeeh et al., 2013)  with-
out altering basal metabolic activity (Kelly et al., 1994). The use of
NOS inhibitors in vivo has the potential to assess the contribution
that NO plays in mediating increases in cerebral blood ﬂow and
hyperemic responses to cognitive activity in  response to  ﬂavonoid
intervention. Applying such an approach to polyphenol clinical
trials will provide a clearer mechanistic understanding of how
ﬂavonoid intake acutely mediates cognition and how such transient
blood ﬂow alterations may  underpin longer-term improvements in
humans.
Recent datasets indicate that  high ﬂavanol intake (495 mg)  is
associated with improvements in  human executive function and
episodic memory at 2 h post-consumption, compared to a  low
ﬂavanol control (23 mg)  (Lamport et al., 2015). Similar data fol-
lowing anthocyanin intake (755 mg;  delivered and controlled as
blueberry) indicate that cognitive improvements are manifested
at 5 h post intake reaching signiﬁcance already at 1 h (Lamport
et al., 2015). The time-course of these cognitive effects, along
with Spencer’s recent peripheral vascular function/blood ﬂow data,
using ﬂow-mediated dilatation (FMD) (Rodriguez-Mateos et al.,
2013)  suggested that the modulation of peripheral blood ﬂow and
cerebrovascular blood perfusion by ﬂavanol-rich foods may  medi-
ate acute improvements in  cognition. In support of this hypothesis,
recent pilot data indicate that ﬂavanol intake (495 mg)  is capa-
ble of increasing cerebral blood perfusion within select regions of
the brain, as measured by arterial spin labelling (Lamport et al.,
2015)  in a  timeframe consistent with both peripheral vascular and
cognitive test performance. Further, a  memory testing procedure
known as pattern separation has recently been identiﬁed which has
the potential to  demonstrate therapeutic response in  men  to com-
pounds which promote hippocampal neurogenesis (Bakker et al.,
2008; Yassa et al., 2011). A  paper has just appeared demonstrating
that one of such tests was  able to  identify positive effects of a  high-
ﬂavanol cocoa preparation in  elderly healthy volunteers (Brickman
et al., 2014). In this study, improved cognitive function with the
cocoa preparation was  accompanied by functional magnetic reso-
nance imageing (fMRI) evidence of enhanced activity in the dentate
gyrus which is the hippocampal site responsible for neurogenesis.
However, to date, no cause-effect relationship has been investi-
gated between ﬂavonoid intake, vascular function and cognitive
performance. In addition, very little is  known about the longer-term
effects of ﬂavonoids on cognitive function in humans, or whether
such effects may  be  sustained in the absence of intake, despite there
has been a  wealth of animal data in support of potential longer term
efﬁcacy (Corona et al., 2013; Rendeiro et al., 2012, 2013; Williams
et al., 2008).
Despite clear evidence regarding the acute vascular effects of
ﬂavonoids shown in humans (Macready et al., 2010) and medium-
term changes in  synaptic plasticity markers demonstrated in
animal studies (Spencer, 2009), the basic mechanisms of action
of ﬂavonoids in humans remains unclear, due to a  lack of precise
causative/mechanistic data. Future work should strive to  determine
the mechanistic basis of ﬂavonoids-induced improvements in cog-
nitive function by investigating the degree to  which peripheral-
and cerebral blood ﬂow induced by ﬂavonoids metabolites plays
in  determining improvements in human cognitive performance, in
particular attention and episodic memory.
5.6. Vitamins
Among vitamins, high dietary intakes of tocopherols are  associ-
ated with a  reduced AD or dementia incidence (Mangialasche et al.,
2011). However, interventional studies using Vitamin E supple-
mentation failed to  report positive effects on the risk of AD (Barnard
et al., 2014)  for vitamin C, although there has been inconsistency
among observational studies relating dietary intake of ascorbic acid
to  improved cognition, some results have favoured an important
role for ascorbic acid in cognitive health. Therefore, further research
focused on investigating the speciﬁc role of ascorbic acid in AD with
special attention to the study design and methodologies, which rep-
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resent an important study limitation, has been suggested to  provide
more conclusive data (Harrison et al., 2014).
The mechanisms that support the relation between vita-
mins B and the brain are mostly related to homocysteine (Hcy)
metabolism, a marker of vitamin B insufﬁciency. Hcy is  catabolized
through a remethylation cycle mediated by  folate and vitamin B12,
which provides methyl-group for several metabolic steps (Levitt
and Karlinsky, 1992). Clinical evidence has demonstrated a  cor-
relation between elevated plasma (Hcy) and the occurrence of
AD and thus, hyperhomocysteinemia has been suggested as an
important risk factor of AD (Obeid and Herrmann, 2006; Seshadri
et al., 2002). Observational studies have  reported that people with
high blood concentrations of Hcy have elevated risk for vascular
disease (Clarke et al., 1991)  and AD (Clarke et al., 1998). These
studies prompted randomized trials to assess whether vitamins
B positively impacted on cognition, but their results have been
mixed. In one of the most recent systematic reviews, 35 cohort
studies with a total number of 14,235 individuals were iden-
tiﬁed (O’Leary et al., 2012). Twenty-one studies were of good
quality of which only 7 showed a beneﬁcial association. This asso-
ciation was more consistent in studies that  included the newer
and more speciﬁc markers of vitamin B12 status such as methyl-
malonic acid (MMA) and holotranscobalamin (holoTC). The most
recent Alzheimer’s Disease International (ADI) report on nutri-
tion and dementia included 4 additional studies that all  showed
a beneﬁcial association of a  higher vitamin B status with less cog-
nitive decline (Alzheimer’s Disease International, 2014). Even after
including those more recent studies still the majority of observa-
tional studies did not  show a  beneﬁcial association. A meta-analysis
was performed on RCTs performed in individuals with or  with-
out cognitive impairment (Ford and Almeida, 2012). Nineteen RCTs
were included and the overall conclusion was that no effect of vita-
min  B supplementation was observed on cognition. Similar ﬁndings
were reported in an earlier Cochrane review (Malouf and Areosa
Sastre, 2003),  which concluded that 4 RCTs provided no evidence
for improvement in people with cognitive impairment or demen-
tia when treated with folic acid with or  without vitamin B12 or
B6. However, a later Cochrane update (Malouf and Grimley Evans,
2008), which included 8 studies concluded that there was  some
effect. For instance, a  better response to cholinesterase treatment
with B vitamins was observed in  some studies including both peo-
ple with AD and without dementia.
After these reviews some additional RCT results were published
(Douaud et al., 2013; Hankey et al., 2013; Walker et al., 2012) of
which two RCTs showed an effect. Several observational studies
have included brain MRI  and all showed at least some beneﬁcial
associations (de Lau et al., 2009; Sachdev et al., 2002; Smith et al.,
2010; Tangney et al., 2011; Vogiatzoglou et al., 2008).
Some other conﬂicting results have been released by the Folate
after Coronary Intervention Trial (FACIT) (n = 800) which reported
that folic acid had a signiﬁcant effect on memory (Durga et al.,
2007). This study showed that people who were treated with folic
acid and had high levels of Hcy (which is a  risk factor for dementia
and heart disease) had better cognitive function over a  2–3 years
period than those who were not  treated.
One recent RCT (VITACOG trial) including 168 MCI  patients has
been performed that included brain  MRI  as an outcome measure
and showed that after 24 months of vitamin B supplementation
patients showed a  30% slower rate of brain atrophy (Smith et al.,
2010). Additionally, in  the same study it was demonstrated that
vitamin B supplementation was able to slow the cognitive and
clinical decline in  people with MCI, in particular in  those with
elevated Hcy levels (de Jager et al., 2012). Despite this, reliable evi-
dence requires large trials, avoidance of bias and sub-group analysis
and meta-analyses of such trials. A recent meta-analysis by Clarke
et al. (Clarke et al., 2014) included all B-vitamin trials assessing
effects on cognitive function. It  assessed the effects of B-vitamins
on individual domains of cognitive function, global cognitive func-
tion and cognitive ageing. Dietary supplementation with vitamins B
to lower Hcy levels had no signiﬁcant effect on individual domains,
global cognitive function or cognitive ageing. Overall, it was  shown
that vitamins B had no beneﬁcial effect on  either cognitive ageing
(Clarke et al., 2014) or vascular disease (Clarke et al., 2010).
Another vitamin that has been widely investigated is vitamin
D. Currently a large proportion of populations are vitamin D deﬁ-
cient, and in  particular the elderly (van der Wielen et al., 1995).
Some vitamin D receptors are located in the brain and many mech-
anisms that may  support its role in  the brain have been identiﬁed
(Brouwer-Brolsma and de Groot, 2015). Regarding observational
evidence, Balion et al. (2012) identiﬁed 37 studies that could be
included in  his meta-analysis. There was a  large heterogeneity, in
particular in  different cognitive tests that were used as an outcome
measure. Results based on 8 studies using the MMSE  showed that
participants with 25-hydroxyvitamin D  (25(OH)D) concentrations
>50 nmol/L had a  higher MMSE  score than those with concentra-
tions <50 nmol/L.
5.7. -3 PUFAs
Long-chain -3 PUFAs, EPA and DHA have been associated with
decreased brain inﬂammation and preservation of the integrity and
function of neuronal membranes (Janssen and Kiliaan, 2014).For
example, DHA which is a  key component of phospholipid cell mem-
branes, may modulate the amyloid precursor protein (APP), thereby
reducing formation and increasing clearance of -amyloid, the
main component of AD plaques (Alzheimer’s Disease International,
2014).
Observational evidence has been focused on the association
between ﬁsh  long-chain -3 PUFA intake or -3 PUFA status and
cognitive functioning, cognitive decline or  dementia. More than 30
studies have been performed and the vast majority of studies have
showed beneﬁcial associations (van de Rest et al., 2012). In the ﬁrst
Cochrane review on -3 PUFA trials that was  published in  2006,
no single RCT could be included (Lim et al., 2006). That review was
updated in 2012 and at that  time the ﬁrst RCTs in  non-demented
elderly and with a  study duration of at least 6 months were pub-
lished. In total, three RCTs were included with a total of  3536
participants. The conclusion was  that -3 PUFA supplementation
had no effect on cognitive functioning (Sydenham et al., 2012). In
the same year Mazereeuw et al. (2012) performed a  meta-analysis
and included cognitively impaired and demented individuals as
well. They included 10 RCTs and did not see an overall beneﬁt
for immediate recall after -3 PUFA supplementation in  healthy
or  demented elderly. However, they found an effect on the speciﬁc
cognitive domains for immediate recall, attention and processing
speed in cognitively impaired non-demented individuals.
The research ﬁeld is currently advancing by not only the inclu-
sion of batteries of cognitive tests as an outcome measure, but also
including MRI  techniques. Several observational studies including
brain MRI  have been performed and all have showed at least some
beneﬁcial associations (Conklin et al., 2007; Pottala et al., 2014;
Samieri et al., 2012; Tan et al., 2012; Titova et al., 2013; Virtanen
et al., 2008). Also, one RCT has been performed in  65 healthy elderly
and with a  study duration of 26 weeks (Witte et al., 2013). In  this
study beneﬁcial effects were found on executive functioning, on
the MRI  measures of gray matter atrophy, and on white matter
microstructural integrity.
5.8. Calorie restriction
Diet including total intake, frequency, and content has emerged
as an important environmental factor that can impact brain plas-
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ticity, including adult hippocampal neurogenesis (AHN) (Stangl
and Thuret, 2009; Zainuddin and Thuret, 2012). The level of
AHN decreases with age and has been linked directly to cogni-
tion and mood (Murphy et al., 2014). In rodents, an increase of
neurogenesis in the hippocampus is  associated with improved
learning/memory abilities, whereas a  decrease is associated with
symptoms of depression (Mateus-Pinheiro et al., 2013; Snyder
et al., 2011).  Therefore, modulation of AHN by  diet emerges as
a potential mechanism by which nutrition impacts on mental
health (Murphy et al., 2014). Synapse formation is  a  key site in
the initiation of the neurodegenerative process occurring during
AD pathology, and then, calorie restriction (CR) may  have signiﬁ-
cant effects on the disease pathology via modulation of AHN and
synaptic plasticity (Maruszak et al., 2014). Wu et al. (2008b) found
that CR (30% for 4 months) in  the transgenic mouse model of AD sig-
niﬁcantly attenuated ventricle enlargement, hippocampal atrophy,
and caspase-3-activation. For example, the effect of CR,  limiting the
intake compared to baseline unrestricted or ad libitum consump-
tion, together with maintained levels of vitamin, mineral, or other
essential biomolecules has appeared to increase AHN. Furthermore,
CR seems to improve the resilience of synapses to metabolic and
oxidative damage and modulates the structure and functional sta-
tus of synapses (Mattson, 2012).  Moreover, CR has demonstrated
to  induce the differential expression of genes of which 25% are
involved in synaptic plasticity (Park and Prolla, 2005). Mice have
showed improved working memory after long-term CR (Kuhla
et al., 2013; Steinman et al., 2011). An increase in  the expression
of NMDA receptors, essential for LTP and synaptic plasticity, has
been found in the hippocampus of 60% CR obese rats as compared
to  age-matched ad libitum fed  animals (Yilmaz et al., 2011). Taken
together, while still further research is warranted to elucidate the
mechanisms by which some dietary factors induce brain plasticity,
animal and supported epidemiological studies have demonstrated
that multiple dietary regimens and components increase the levels
of AHN, enhance brain plasticity and promote synaptic function in
the context of  ageing.
5.9. Ketogenic diets
Very-low-carbohydrate ketogenic diets (VLCKD) have been used
for many decades especially after the 1970s when they became
popular for weight loss (Atkins, 1972). But it was  in  the early 1920s
when the importance of the use of these diets became relevant from
the clinical point of view and were successfully used to treat many
pathological conditions such as epilepsy (Hartman et al., 2007),
diabetes (Dashti et al., 2006), CVD factors (Paoli et al., 2011) and
neurological diseases (Baranano and Hartman, 2008). The review
by Paoli et al. (2013) considers possible mechanisms for the thera-
peutic actions of the ketogenic diet (KD) on weight reduction and
different diseases such as CVD and diabetes. Although, the exact
mechanisms of action of the KD are still poorly understood recently
reports have suggested that ketone bodies (KB) act as neuropro-
tective agents by  raising ATP levels, diminishing the production of
reactive oxygen species in neurological tissues and enhancing the
regulation of synaptic function though mitochondrial biogenesis
(Bough and Rho, 2007). Moreover, the stimulation of PUFAs synthe-
sis by a KD has been demonstrated to regulate neuronal membrane
excitability mediated by voltage-gated sodium channels (Huffman
and Kossoff, 2006).
However, new research concerning one of these diets, the MCT
ketogenic diet, has recently demonstrated a compelling mech-
anism of action in seizure control (Chang et al., 2015). These
studies show that a  fatty acid provided in  the diet, decanoic
acid (10:0), reduces seizures induced in  hippocampal slices of
rodent. Using the whole cell patch clamp with rat hippocam-
pal slices, decanoic acid reduced excitatory postsynaptic currents
by 38.9 ±  5.5% at 52 g/mL concentration and inhibited -amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors,
which are a target for antiepileptic drugs. This  inhibitory mecha-
nism is speciﬁc to  deﬁned chemical structures, is effective against
multiple AMPA subunit compositions, and is enhanced during
synaptic activation. These results deﬁne how the MCT  diet provides
a way  of controlling seizures by the diet, without the need for the
production of ketones or for pharmacological intervention (Chang
et al., 2015, 2013).
Given that patients with AD show a  higher incidence of  seizures
(Palop and Mucke, 2009), KD may  be  a successful diet for its clin-
ical treatment. Supporting evidence suggests that acute elevation
of serum -hydroxibutyrate (-OHB) (one type of KB) through an
oral dose of MCTs shows cognitive improvements in AD patients.
A recent RCT in 20 patients (55–58 years) diagnosed with prob-
able AD (n  =  15) or MCI  (n = 5)  showed that acute administration
of MCTs (40  g), which led  to elevate -OHB, was positively corre-
lated to  improved cognitive function (Reger et al., 2004).  Another
clinical trial performed in  152 patients with mild to moderate AD
(Henderson et al., 2009) compared the effect of Axona®,  a  medi-
cal food containing a  formulation of MCTs, or placebo and found
that cognitive scores remained stabilized in the Axona® group,
while the placebo groups presented a  decline in cognition, but only
among Apo4(−)  subjects. Although, Axona® formulation has been
reported to be well-tolerated in normal elderly volunteers, the pro-
posed cognitive effect is uncertain in  non-demented elderly people.
Importantly, all these cognitive responses to  increased energetic
substrates were strongly dependent on APOE genotype (Craft et al.,
2000).
5.10.  Multicomponent diets
The important role of diets and healthy lifestyle in the preven-
tion of vascular disease development is widely accepted. Already
30 years ago pioneering studies on Greenland Eskimos indicated
that intake of -3 long chain polyunsaturated fatty acids (-3 LCP-
UFAs) from ﬁsh and wildfowl had protective effects against CVD
(Bang et al., 1971, 1980). More recently, the Mediterranean diet
containing ﬁsh, olive oil and nuts as important lipid containing
components, has been shown in several prospective worldwide
studies to be inversely associated with CVD (Estruch et al., 2013)
and to have a  strong protective function against hypertension, obe-
sity, and AD risks (Calton et al., 2014; Grosso et al., 2014; Koliaki and
Katsilambros, 2013; Scarmeas et al., 2009). Moreover a  recent thor-
ough systematic review and meta-analysis suggests that a higher
adherence to the Mediterranean diet may  affect not only the risk of
AD, but is  also associated with a reduced risk of developing MCI and
AD, and a reduced risk of progressing from MCI  to AD (Singh., et al.,
2014; Solfrizzi and Panza, 2014).Dietary lipids are also starting to
be  highly recognized in  nutrition thanks to their direct actions on
synaptic function and cognitive processes (de Waal et al., 2014;
Kamphuis and Scheltens, 2010; Shah, 2011; Shah et al., 2013; van
Wijk et al., 2014; Wurtman, 2008). Contrarily, diets high in  satu-
rated fat are becoming notorious for reducing molecular substrates
that support cognitive processing and increasing the risk of neuro-
logical dysfunction in  both animals and humans (Gomez-Pinilla,
2008; Li et al., 2013; Wu et al., 2008a). Dietary factors can affect
multiple brain processes by regulating neurotransmitter pathways,
synaptic transmission, membrane ﬂuidity and signal-transduction
pathways. Recent data published by the group of Kiliaan et al.
(Jansen et al., 2014; Wiesmann et al., 2013; Zerbi et al., 2014) and
latest data in mice models for AD and vascular impairment, have
shown that the treatment with multicomponent diets promotes
neuroprotection by decreasing inﬂammation, restoring cerebral
blood ﬂow and volume, inhibiting neurodegeneration, and enhanc-
ing neural plasticity by increasing neurogenesis (Wiesmann et al.,
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2016). In particular, they (Zerbi et al., 2014) showed that a speciﬁc
combination diet (FortasynTM) containing membrane precursors
such as -3 fatty acids and uridine monophosphate plus cofac-
tors for membrane synthesis was able to  inhibit/reverse the early
functional connectivity reduction and cerebral blood ﬂow (CBF)
impairment in mice (both parameters were apparent already before
cognitive decline).
Thus, diet may  serve as preventive strategy at very early,
non-symptomatic phases of AD, especially because there are no
currently effective treatments for AD. Therefore, future research
should focus on the early, asymptomatic phase of the disease
especially on the (cardio) vascular risk factors like atherosclero-
sis, hypertension, obesity and T2DM being modiﬁable via changes
in lifestyle factors such as diet.
5.11. Exercise
Gradual and progressive memory decline is  often one of the ear-
liest hallmarks in AD which can strongly inﬂuence the quality of life
of an individual. Several lifestyle factors may  interfere with the rate
of cognitive decline in the elderly such as diet and physical activity.
The Study of Elderly’s Memory impairment and Associated Risk
factors (SEMAR) has been set up in  Indonesia and included 719
participants (aged 52–99 years) from different ethnic backgrounds
in rural and urban Java (Jakarta, Citengah and Yogyakarta) (unpub-
lished data). These cohorts as well as other similar cohorts in  China,
Netherlands, UK and USA, have recently been set up to investi-
gate whether lifestyle factors in  different ethnic/cultural cohorts
were associated with a  reduced risk of dementia (ongoing study)
and found that the combination of exercise and eating fruit had
a cumulative effect in reducing dementia risk in Indonesia people
(unpublished data).
Many observational studies (Clifford and Hagervorst, 2009;
Hogervorst et al., 2012)  have showed a  reduced risk  of dementia
in people who exercise. For instance, in  Indonesia it was found that
older people who engaged in sports had a  halved risk of demen-
tia (Hogervorst et al., 2012), which was similar to data from the
US and other countries (Barnes and Yaffe, 2011). However, several
reviews have also showed that only 50% of the studies including an
exercise intervention showed cognitive improvement in older peo-
ple (Clifford and Hagervorst, 2009; Hogervorst et al., 2012)  which
might be due to poor adherence to the program. Similarly, the
group of Hogervorst et al. (2012) found that resistance band (mus-
cle strength) exercises 2–3 times/week for 20–30 min  improved
memory function. In addition, exercise may  be effective as a  pre-
ventive activity as it can lower blood pressure and total cholesterol,
can reduce abdominal fat and improve immune and lung function,
as well as improve cardiovascular function, which improves cere-
bral blood ﬂow. As discussed previously, all these factors may  be
implicated in dementia. Importantly, exercise can also directly pro-
mote outgrowth of nerve cells which allows better communication
between brain cells, which is  often reduced in  dementia (Clifford
and Hagervorst, 2009). Even in  people who have already developed
dementia, walking and muscle strengthening exercises are likely to
have positive effects on cognitive abilities (Hogervorst et al., 2012).
In conclusion, risk factors for AD are similar to those for CVD
(heart), such as high blood pressure, smoking, high cholesterol and
obesity and need to be treated in midlife at the latest to reduce
the risk of dementia later in life. A  multi-disciplinary change in
lifestyles (combining exercise with healthy diets) with a  focus on
midlife is the most important factor for prevention of dementia.
Therefore, changing the lifestyle to a  healthier one which includes
exercise and a healthy diet can reduce the risk for both heart disease
and dementia.
6. Methodological challenges in nutritional interventions
on cognition
Epidemiological studies have shown that a  lower risk of demen-
tia or cognitive decline is associated with diets relatively low in
energy (Luchsinger et al., 2002)  but rich in several key nutrients
and food derived non-nutrient bioactives, including long-chain -
3 PUFA (Cunnane et al., 2009; Dacks et al., 2013), vitamins B (Clarke,
2008),  antioxidants such as vitamins C, E  (Mangialasche et al., 2010)
and carotenoids (Li et al., 2012), and polyphenols (Joseph et al.,
2009). However, most RCTs that have administered these dietary
components as supplements have yielded disappointing results on
cognition so far, (Barberger Gateau et al., 2013; Clarke et al., 2014;
Sydenham et al., 2012). There are, however, some notable interest,
particularly in the Memory Improvement with DHA Study (MIDAS)
(Yurko-Mauro et al., 2010), the Souvenaid® combination of  nutri-
ents in mild AD (Olde Rikkert et al., 2015; Scheltens et al., 2010,
2012), and the Prevention with Mediterranean Diet (PREDIMED)
study (Valls-Pedret et al., 2015). Thus, epidemiological data and
these “success stories” from a  limited number of RCTs, provide the
justiﬁcation and valuable methodological insight. In addition, they
could be used in combination with the implementation of more
robust ‘ﬁt-for-purpose’ RCTs to  demonstrate the impact of diet on
cognition in  older persons. Such interventions should be carefully
powered and of adequate duration (chosen based on physiologi-
cal insights into likely changes in  the primary outcome measures
during the intervention period) in order to  prevent false negative
ﬁndings. Three further aspects should be considered: 1) improv-
ing  inclusion criteria in  RCTs, 2) optimizing the composition of the
nutritional supplement or the diet to be evaluated, and 3) deﬁning
more sensitive primary and secondary outcomes which are also
important methodological considerations that will be  discussed
below.
Identiﬁcation of individuals at high risk of cognitive decline or
dementia, who should be included in RCTs assessing the impact
of nutrition, who are  likely to be sensitive and gain most beneﬁt
from the intervention should be based on early markers of dis-
ease progression, low dietary intake or  blood levels of  selected
dietary components of interest, or  genetic characteristics. The nat-
ural history of the pathophysiology of AD spreads over decades
during which A accumulates in the brain before the ﬁrst cognitive
symptoms appear (Jack et al., 2013, 2010a,b) raising the question
of the optimal window for prevention or the progression from the
preclinical, ‘at-risk’ phase to a  clinical diagnosis of disease. It is
virtually impossible to  demonstrate the efﬁcacy of primary pre-
vention in  regard to  cognitive decline. Thus, the main target of
RCTs should be the secondary prevention, at a very early stage of
cognitive decline. The MIDAS included middle-aged adults (aged
55 years) with a subjective memory complaint and preserved gen-
eral cognitive function but a  logical memory baseline score lower
than that of normal younger adults (Yurko-Mauro et al., 2010) to
explore the effect of DHA consumption (900 mg/day) for  24 weeks.
These individuals also had low regular ﬁsh consumption, less than
200 mg/day DHA. After completion of the trial, those receiving DHA,
scored signiﬁcantly higher on several tests of memory than the con-
trol group. The use of genetic variation as an inclusion/exclusion
criteria could also be considered, since several epidemiological
studies and at least one RCT have suggested that the beneﬁt of
supplementation with DHA on cognition could be limited to non-
carriers of the 4 allele of the APOE4 gene, the main genetic risk
factor for AD (Barberger Gateau et al., 2011).
Epidemiology also allows characterization of healthy diets
providing optimal combinations of foods and nutrients that are
associated with better cognitive performance (Alles et al., 2012),
providing the rationale for RCTs using combinations of supple-
ments rather than single nutrients. The most famous example is the
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Mediterranean diet, which has been associated with lower risks of
dementia or cognitive decline in several epidemiological studies,
mostly in Europe and the US (Feart et al., 2010; Lourida et al., 2013;
van de Rest et al., 2015). However, there is great heterogeneity in
the deﬁnition of the “Mediterranean diet” between studies espe-
cially in non-Mediterranean countries. The PREDIMED NAVARRA
RCT in Spain, demonstrated that  randomized participants who fol-
lowed a Mediterranean diet enriched with virgin olive oil or nuts
scored signiﬁcantly better than the control group following a low-
fat diet on a global cognitive score 6.5 years later (Valls-Pedret et al.,
2015). Few RCTs have evaluated the impact of multivitamin supple-
ments on cognition (Grima et al., 2012). For instance, Souvenaid®
which contains -3 PUFA (EPA and DHA), B-vitamins, a  mixture of
antioxidants, and uridine monophosphate (UMP), was formulated
to improve synapse formation and function (Cansev et al., 2015;
Wurtman et al., 2009).  A 24-week RCT conducted in patients with
mild AD showed that the group receiving Souvenaid® scored signif-
icantly better than the placebo group on the memory domain of the
neuropsychological test battery, the primary outcome (Scheltens
et al., 2012).  The study also showed improvement on measures
of functional connectivity (Scheltens et al., 2012),  functional brain
network organization (de Waal et al., 2014), and sustained mem-
ory improvement until 48 weeks in  an open label extension study
(Olde Rikkert et al., 2015). This was the second study in  mild AD
with this intervention and conﬁrmed the results of a proof-of-
concept study which showed improved memory performance after
12 weeks (Scheltens et al., 2010). As these studies were conducted
in subjects with early AD, more research is  needed to  deﬁne the
optimal combination and doses of nutrients that could contribute
to  delay cognitive decline in older persons without AD diagnosis.
In  the case of EPA +  DHA, vitamin D and B vitamins, although
there is relatively consistent epidemiological evidence to exhibit
their independent impacts on cognition, RCTs have generally failed
to demonstrate any efﬁcacy.
Identiﬁcation of relevant and sensitive biomarkers of disease
progression, based on knowledge of the speciﬁc molecular and
physiological targets of the intervention of interest, can optimize
the choice of primary and secondary outcomes in RCTs. MRI  and
fMRI can provide evidence of the impact of nutrients on brain
structure and function The rate of brain atrophy was the pri-
mary outcome of the Hcy and B vitamins in cognitive impairment
(VITACOG) study (Smith et al., 2010)  which found that vitamin
B intake in the active treatment group was associated with 30%
less brain atrophy per year than in those receiving the placebo.
The effect on brain atrophy and cognitive function was  mainly
observed in those with higher baseline homocysteine levels, which
were lowered by vitamin B treatment (de Jager et al., 2012; Smith
et al., 2010). However, some RCTs have yielded discordant results
regarding their impact on mechanisms of action and cognition. The
concentration of F2-isoprostane in  CSF, a  marker of oxidative stress
(lipid peroxidation), has been proposed as a  sensitive but not spe-
ciﬁc biomarker of age-related brain injury (Li et al., 2014). In an RCT,
78 patients with mild to moderate AD were randomized to  receive a
high dose antioxidant mixture (800 IU/d vitamin E, 500 mg/d vita-
min  C, and 900 mg/day -lipoic acid) or 400 mg/d Coenzyme Q,
another antioxidant compound, or  a placebo (Galasko et al., 2012).
After 16 weeks, those receiving the antioxidant mixture had sig-
niﬁcantly decreased F2-isoprostanes in CSF as expected, but an
accelerated cognitive decline. Thus, biomarkers should always be
used in combination with cognitive outcomes.
This lack of positive results in RCTs may  be due to too short trial
duration, not appropriate target group, use of an inadequate dose,
lack of efﬁcacy of single nutrients and/or not  sufﬁciently sensitive
methodology to  measure the outcomes. However, the identiﬁca-
tion of all these limitations will allow a better performance of future
intervention trials. In  addition, there is  still need  for well-designed
Table 1
Contribution of epidemiology to design more efﬁcient RCTs assessing the impact of
nutrition on cognition.
What epidemiology tells us What RCTs should do
Lower intake or blood levels of
some nutrients are associated
with higher risk of cognitive
decline or dementia
⇒ Target individuals with speciﬁc
nutritional insufﬁciency, based on
dietary or biological data
Signiﬁcant cognitive decline is  a
late event in  neurodegenerative
diseases
⇒Target at risk individuals with
more sensitive neuropsychological
tests and biomarkers
Interaction between -3  PUFA
status and APOE4
⇒Stratify RCTs according to APOE4
genotype and probably other single
nucleotides polymorphisms (SNPs)
Healthy diets are associated with
lower risk of cognitive decline or
AD
⇒Use dietary supplements
providing similar combinations of
nutrients
AD is a  multi-factorial disease
whose natural history spreads
over decades
⇒Use early and speciﬁc outcomes:
–  biomarkers of disease
progression
– biomarkers of mechanisms of
action (oxidative stress,
inﬂammation, insulin resistance,
lipids.  . . etc.) in combination
with cognitive outcomes
trials that: a)  have long intervention periods (at least >1.5 year), b)
target at risk groups (mild cognitively impaired or nutrient deﬁ-
cient subjects), c) use harmonized cognitive test batteries (de Jager
et al., 2014), d) include biomarkers and/or imaging measures, e)
use a multi-nutrient or food pattern approach or  a  multi-domain
approach, and f) whose design is  aligned with speciﬁc mechanisms.
Findings from epidemiological studies can be used to design more
efﬁcient RCTs assessing the impact of combinations of nutrients
in  well-targeted individuals, using both biomarkers and cognitive
assessment as outcomes (Table 1).
7. Conclusion
Decline in cognitive abilities with age occurs in healthy indi-
viduals throughout the adult lifespan. Moreover, the line between
normal and pathological ageing is not well-deﬁned as neuro-
logical diseases start years before any clinical symptoms arise.
Several health conditions such as CVD, diabetes or  obesity are
closely related to  cognition. Therefore, when identifying dietary
approaches to promote healthy brain ageing a  holistic approach
should be  considered including nutrition, exercise and lifestyle
factors, which not only target the brain but also overall cardio-
metabolic health (Fig. 1).
The mechanisms associated with normal ageing, including
oxidative stress, neuroinﬂammation and vascular dysfunction are
the same as those contributing to the development of neurological
diseases. However, in these pathological conditions, the mecha-
nisms contributing to ageing are  exacerbated and triggered by
different factors which might be genetic or environmental.
Preclinical studies in animals have consistently demonstrated
the positive impact of several dietary components on cog-
nitive performance and epidemiological studies have showed
successful association of select dietary patterns with cognitive
status. Particularly there is  reasonable evidence that consuming
Mediterranean-style diets protects against cognitive impairment.
RCTs approaches have showed mixed results with intervention
with single dietary components generally disappointing while
some multi-nutrient/non-nutrient interventions have yielded
more encouraging results. These observations are consistent with
the results from epidemiological studies indicating that an adher-
ence to dietary patterns, rather than adequate intake of  single
Please cite this article in  press as: Vauzour, D., et al., Nutrition for the ageing brain: Towards evidence for an optimal diet. Ageing Res.
Rev. (2016), http://dx.doi.org/10.1016/j.arr.2016.09.010
ARTICLE IN PRESSG ModelARR-710; No. of Pages 19
14 D. Vauzour et al. / Ageing Research Reviews xxx (2016) xxx–xxx
Fig. 1. Overview of links between lifestyle interventions on cognition and healthy brain function during ageing.
dietary components may  be the most effective means of protecting
against cognitive decline. A major objective of future research is
to deﬁne the nutritional requirement for healthy cognitive ageing,
and to translate these into effective dietary recommendations.
RCTs are the gold standard to probe the efﬁcacy of drugs but
it may  not be the same for dietary components. In terms of pri-
mary prevention, it is logistically difﬁcult to establish the effect
of nutrition on cognition through RCTs which would require par-
ticipants follow up for potentially decades. In terms of secondary
prevention, targeting individuals at high risk of cognitive decline
and learning from epidemiology as suggested in the last section of
this review should allow a  relatively rapid impact on cognition to
be established.
Finally, it is the aim of this group to continue with the revision of
the state of the art on nutrition for the ageing brain by organizing a
follow-up workshop. In particular, mechanisms of ageing and their
interaction with nutrients will be revisited, and new avenues and
mechanisms of cognitive ageing that may  be  inﬂuenced by nutrition
will be identiﬁed.
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